All GLG News Analyses Filed Under: Cardiology

Percutaneous valve repair – next battle among cardiovascular device companies?

October 4, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology | www.medicalnewstoday.com

By acquiring promising technology in the percutaneous valve arena, as well as enjoying an already established reputation among interventional cardiologists, Abbott will position itself as a major player in an emerging technology market, and become a comprehensive provider for interventional cardiology...

Will the alternative become a leader?

October 1, 2009

Analysis by:GLG Expert Contributor

Analysis of:  EMEA recommends approval of Sanofi-aventis' dronedarone for atrial fibrillation | www.pharmabiz.com

Introducing dronedarone in treatment of atrial fibrillation will provide solution for  many patients with atrial fibrillation who were undertreated due to their contraindications for amiodarone or it's adverse effects.

A new treatment for a major problem.

September 30, 2009

Analysis by:GLG Expert Contributor

Analysis of:  ACC: Device May Prevent Stroke in AF Patients | www.medpagetoday.com

Atrial fibrillation is a very common condition that significantly increase the risk of stroke, especially in the older population. Vitamin K antagonists are the only current effective treatment in the higher risk population to reduce stroke. Any new treatment has a huge potential to help reduce risk,...

How much market will MADIT-CRT drive?

September 30, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Cardiac-Resynchronization Therapy for the Prevention of Heart Failure Events | content.nejm.org

While this trial had a positive endpoint, it was not a mortality endpoint.   A major defect is a lack of a medical therapy alone arm.  That said, prevention of heart failure episodes is a laudable goal and given the expense to the US system of CHF, this could be a worthwhile treatment, however thenumber...

Convenient for patients, and maybe for doctors

September 26, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Novartis gets FDA approval for combo pill valturna to treat high BP | www.pharmabiz.com

Undoubtedly powerful combination which will help control BP in many patients who have resistant or difficult to control hypertension.

New twist in ABCD algorithm

September 21, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Novartis gets FDA approval for combo pill valturna to treat high BP | /councils.glgroup.com/news/ExternalLink.mvc/Article/303185?utm_campaign=newswatch

The FDA have approved a combination of Aliskiren and Valsartan in a fixed dose preparation for the treatment of hypertension. Although initial safety data show efficacy and tolerability in an 8-week study, outcome data on real-life use and in "non-standard" cases of hypertension or other disorderssuggests...

The Logical Next Step for Abbott

September 15, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology | www.medicalnewstoday.com

With this acquisition Abbott establishes its position as a major player in the field of interventional cardiology and treatment of structural heart disease.The field of structural heart disease therapy is the fastest growing area of interventional cardiology and Abbott is getting in at the ground floor.In...

Abbot will benefit in long run with acquisition of Evalve.

September 15, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology | www.medicalnewstoday.com

The acquisition will definitely have a significantly beneficial effect on the market standing as well as product portfolio of Abbot. Even though at the present time this technique developed by Evalve Inc. is useful only for a very small subset of patients, eventually Abbott can develop it furtherto...

Good idea in a large company

September 14, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology | www.medicalnewstoday.com

Good ideas and good products are better improved and marketed as a products of a large company, but....

Abbott to become a comprehensive structural heart disease provider

September 14, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology | www.medicalnewstoday.com

With the acquisition of Evalve, Abbott will position itself on the lead for structural heart disease.

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 597